RPS12 and brucellosis: However, the improved MALDI-TOF MS based screening for the B. melitensis Rev.1 vaccine strain and other streptomycin resistant B. melitensis field isolates with ribosomal protein S12 variants may reduce the risk of an inadequate first line therapy in human brucellosis, since streptomycin is commonly used in the antibiotic regimen applied for patients infected with Brucella (Skalsky et al., 2008; Meng et al., 2018).